Gilead proves it's one tough con­tender in HIV, but don't count GSK out of the fight

Look­ing to de­fend it­self against a new HIV drug from Gilead, Glax­o­SmithK­line’s $GSK Vi­iV post­ed a near mir­ror im­age of vi­ral sup­pres­sion for its two-drug com­bo of Tivicay (do­lute­gravir) tied to J&J’s rilpivirine com­pared with the re­sults from the three- and four-drug cock­tails it hopes to re­place. But Gilead $GILD struck first, re­leas­ing the first look at some im­pres­sive Phase II da­ta on their ri­val drug bicte­gravir.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER